UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 800 shares, a decline of 73.3% from the October 31st total of 3,000 shares. Based on an average trading volume of 58,500 shares, the days-to-cover ratio is currently 0.0 days.

UCB Stock Up 2.3 %

Shares of UCB stock opened at $97.55 on Friday. The firm’s fifty day simple moving average is $93.71 and its 200-day simple moving average is $84.13. UCB has a 12 month low of $36.70 and a 12 month high of $99.40. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.